Trial Profile

A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NDI-101150 (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Nimbus Therapeutics

13 Jan 2025 According to a Schrodinger media release, updated data from this study presented at the Society for Immunotherapy of Cancer Annual Meeting.
09 Jan 2025 Status changed from active, no longer recruiting to completed.
25 Nov 2024 Planned End Date changed from 1 Dec 2024 to 1 May 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com